

# Stefan Karl Christian Alig

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/873507/publications.pdf>

Version: 2024-02-01

20  
papers

411  
citations

1040018

9  
h-index

888047

17  
g-index

20  
all docs

20  
docs citations

20  
times ranked

485  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inferring gene expression from cell-free DNA fragmentation profiles. <i>Nature Biotechnology</i> , 2022, 40, 585-597.	17.5	63
2	The molecular ontogeny of follicular lymphoma: gene mutations succeeding the <i>BCL2</i> translocation define common precursor cells. <i>British Journal of Haematology</i> , 2022, 196, 1381-1387.	2.5	5
3	Phased variants improve DLBCL minimal residual disease detection at the end of therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7565-7565.	1.6	1
4	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. <i>Nature Biotechnology</i> , 2021, 39, 1537-1547.	17.5	151
5	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2605-2616.	1.6	37
6	Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma. <i>Blood</i> , 2021, 138, 233-233.	1.4	6
7	Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma. <i>Blood</i> , 2021, 138, 6-6.	1.4	15
8	Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing. <i>Blood</i> , 2021, 138, 37-37.	1.4	0
9	Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models. <i>Blood Advances</i> , 2020, 4, 4451-4462.	5.2	8
10	Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA). <i>Blood</i> , 2020, 136, 49-50.	1.4	3
11	Impact of age on clinical risk scores in follicular lymphoma. <i>Blood Advances</i> , 2019, 3, 1033-1038.	5.2	18
12	Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucef Therapy. <i>Blood</i> , 2019, 134, 550-550.	1.4	13
13	Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA. <i>Blood</i> , 2019, 134, 552-552.	1.4	5
14	Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL. <i>Blood</i> , 2019, 134, 1600-1600.	1.4	3
15	Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling. <i>Blood</i> , 2019, 134, 551-551.	1.4	9
16	Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 491-491.	1.4	0
17	Impact of age on genetics and treatment efficacy in follicular lymphoma. <i>Haematologica</i> , 2018, 103, e364-e367.	3.5	10
18	Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. <i>Blood</i> , 2018, 132, 1695-1702.	1.4	49

#	ARTICLE	IF	CITATIONS
19	Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial. <i>Blood</i> , 2018, 132, 4096-4096.	1.4	0
20	The Tyrosine Phosphatase SHP-1 Regulates Hypoxia Inducible Factor-1 $\alpha$ (HIF-1 $\alpha$ ) Protein Levels in Endothelial Cells under Hypoxia. <i>PLoS ONE</i> , 2015, 10, e0121113.	2.5	15